Biotech, Health-Care SPAC Deals Need Top Due Diligence: Report

Due Diligence

SPACs increasingly are being used to take private biotech and health-care companies public, but they raise special due diligence issues because the companies are highly regulated and their products affect patients, Bloomberg reports, citing Reed Smith attorneys. They outline several key aspects that need extra scrutiny.

Due diligence for biotechnology companies is critical because they tend to be highly regulated by multiple government agencies, and the products can directly affect patients’ health and well-being. Without proper due diligence, latent problems could cause issues at any moment, putting the company and its investors’ funds at risk. Read more.

Related Posts